Immunotherapy drug shows promise in keeping early lung cancer at bay
NCT ID NCT02504372
First seen Nov 01, 2025 · Last updated May 24, 2026 · Updated 30 times
Summary
This study tested whether the immunotherapy drug pembrolizumab could help prevent non-small cell lung cancer from coming back after surgery. About 1,177 people with stage IB to IIIA lung cancer who had their tumor removed received either pembrolizumab or a placebo. The main goal was to see if the drug could lengthen the time before the cancer returned or the patient died.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
Explore the condition pages connected to this study.